FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989005623> ?p ?o ?g. }

• W2989005623 endingPage "1116" @default.
• W2989005623 startingPage "1116" @default.
• W2989005623 abstract "Introduction The bleeding phenotype of type 1 von Willebrand disease (VWD) patients is very heterogeneous. We hypothesized that part of this heterogeneity is explained by variability in response of von Willebrand factor (VWF) and factor VIII (FVIII) levels to stress during hemostatic challenges. Patients who have a strong increase in VWF and FVIII levels during hemostatic challenges, may have less frequent or less severe bleeding episodes compared to patients who have a smaller increase in VWF and FVIII levels. Therefore, we investigated whether VWF and FVIII levels after desmopressin, which mimic in vivo hemostatic response during hemostatic challenges, are associated with the bleeding score, and therefore may explain part of the heterogeneity in bleeding phenotype of type 1 VWD patients. Methods In this retrospective cohort study, we included type 1 VWD patients of all ages who were diagnosed and treated in the Erasmus University Medical Center. All patients had a hemorrhagic diathesis or family history of VWD and historically lowest VWF antigen (VWF:Ag) and/or VWF Ristocetin Cofactor activity (VWF:RCo) ≤ 0.30 IU/mL with VWF activity/ VWF antigen ratio above 0.60. All patients participated in the Willebrand in the Netherlands (WiN) study, in which a self-administered Tosetto bleeding score was assessed. Results We identified 173 eligible type 1 VWD patients in our treatment center who participated in the WiN study. After exclusion of 50 patients who did not receive a desmopressin test dose, and 1 patient who did not have a bleeding score assessment, we included 122 type 1 VWD patients. Table 1 shows the patient characteristics. Higher FVIII activity during the complete time course (i.e. one, three and 5-6 hours) after desmopressin, and higher VWF and FVIII levels combined at three hours after desmopressin, were associated with a lower bleeding score, respectively β=-0.9 (95% CI: -1.7; -0.1) and β=-1.2 (-1.9; -0.5), both adjusted for age, sex, BMI and comorbidities. FVIII:C at three hours after desmopressin was significantly associated with a lower bleeding score: β=-1.5 (-3.0; -0.1), whereas VWF levels were not associated (Figure 1). Moreover, patients with VWF and FVIII levels in the highest quartile three hours after desmopressin administration had a lower bleeding score compared to other patients (Figure 2). The largest difference was found for FVIII:C: β=-5.1 (-8.4; -1.8), adjusted for age, sex, BMI, comorbidities and baseline FVIII:C. These patients also less often had an abnormal bleeding score: OR=0.1 (0.0-0.5), adjusted for age, sex, BMI, comorbidities and baseline FVIII:C. Lastly, patients with an increased clearance of VWF, defined as VWF propeptide/VWF:Ag ratio >2.2, had lower VWF:Ag (β=-0.3, -0.6; -0.1), VWF:Act (β=-0.5, -0.7; -0.2), VWF:CB (β=-0.5, -1.0; -0.1) and FVIII:C (β=-0.7, -1.0; -0.4) at three hours after desmopressin administration compared to other type 1 VWD patients, all adjusted for age, sex, BMI and comorbidities. An increased clearance of VWF was also associated with a higher bleeding score: β=3.2 (0.2; 6.2), adjusted for age, sex, BMI, comorbidities and baseline VWF and FVIII levels. Discussion In type 1 VWD patients, the desmopressin induced increase of VWF and FVIII levels is associated with a lower bleeding score. Especially higher VWF and FVIII levels at three hours after desmopressin were associated with a milder bleeding phenotype, suggesting that sustained VWF and FVIII levels after a hemostatic challenge may be important to prevent bleeding. This was strengthened by an association between increased clearance of VWF and a higher bleeding score. Furthermore, patients with VWF and FVIII levels in the highest quartile three hours after desmopressin had 5 points lower bleeding score, and patients with FVIII:C in the highest quartile had 10 times less often an abnormal bleeding score. These results indicate that a good hemostatic response may have important and clinically relevant consequences on the bleeding phenotype, and may compensate for the low baseline VWF and FVIII levels in type 1 VWD patients. In conclusion, VWF and FVIII levels after desmopressin administration, which mimic in vivo hemostatic response to hemostatic challenges, are associated with the bleeding phenotype in type 1 VWD patients. This may partly explain the well-known variability in bleeding phenotype of type 1 VWD patients. Disclosures Atiq: Sobi: Other: Travel grant (ISTH 2019); Professor Heimburger Award 2018 (CSL Behring): Research Funding. Schütte:CSL Behring: Other: Travel grant. Boender:Sobi: Employment; Professor Heimburger Award 2016 (CSL Behring): Research Funding. Kruip:Bayer: Research Funding; Pfizer: Research Funding; Daiichy Sankyo: Research Funding; Boehringer Ingelheim: Research Funding. Leebeek:Shire/Takeda: Consultancy; UniQure: Consultancy; Novo Nordisk: Consultancy; Shire/Takeda: Research Funding; Sobi: Other: Travel grant; CSL Behring: Research Funding." @default.
• W2989005623 created "2019-11-22" @default.
• W2989005623 creator A5002870795 @default.
• W2989005623 creator A5003033827 @default.
• W2989005623 creator A5015860216 @default.
• W2989005623 creator A5019591784 @default.
• W2989005623 creator A5050757013 @default.
• W2989005623 creator A5060379110 @default.
• W2989005623 creator A5090296015 @default.
• W2989005623 date "2019-11-13" @default.
• W2989005623 modified "2023-09-30" @default.
• W2989005623 title "VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD" @default.
• W2989005623 doi "https://doi.org/10.1182/blood-2019-123634" @default.
• W2989005623 hasPublicationYear "2019" @default.
• W2989005623 type Work @default.
• W2989005623 sameAs 2989005623 @default.
• W2989005623 citedByCount "0" @default.
• W2989005623 crossrefType "journal-article" @default.
• W2989005623 hasAuthorship W2989005623A5002870795 @default.
• W2989005623 hasAuthorship W2989005623A5003033827 @default.
• W2989005623 hasAuthorship W2989005623A5015860216 @default.
• W2989005623 hasAuthorship W2989005623A5019591784 @default.
• W2989005623 hasAuthorship W2989005623A5050757013 @default.
• W2989005623 hasAuthorship W2989005623A5060379110 @default.
• W2989005623 hasAuthorship W2989005623A5090296015 @default.
• W2989005623 hasConcept C126322002 @default.
• W2989005623 hasConcept C203014093 @default.
• W2989005623 hasConcept C2776217217 @default.
• W2989005623 hasConcept C2778589496 @default.
• W2989005623 hasConcept C2778702241 @default.
• W2989005623 hasConcept C2778780528 @default.
• W2989005623 hasConcept C2779216453 @default.
• W2989005623 hasConcept C2779394231 @default.
• W2989005623 hasConcept C2779936836 @default.
• W2989005623 hasConcept C2780073493 @default.
• W2989005623 hasConcept C2993802102 @default.
• W2989005623 hasConcept C71924100 @default.
• W2989005623 hasConcept C89560881 @default.
• W2989005623 hasConcept C90924648 @default.
• W2989005623 hasConceptScore W2989005623C126322002 @default.
• W2989005623 hasConceptScore W2989005623C203014093 @default.
• W2989005623 hasConceptScore W2989005623C2776217217 @default.
• W2989005623 hasConceptScore W2989005623C2778589496 @default.
• W2989005623 hasConceptScore W2989005623C2778702241 @default.
• W2989005623 hasConceptScore W2989005623C2778780528 @default.
• W2989005623 hasConceptScore W2989005623C2779216453 @default.
• W2989005623 hasConceptScore W2989005623C2779394231 @default.
• W2989005623 hasConceptScore W2989005623C2779936836 @default.
• W2989005623 hasConceptScore W2989005623C2780073493 @default.
• W2989005623 hasConceptScore W2989005623C2993802102 @default.
• W2989005623 hasConceptScore W2989005623C71924100 @default.
• W2989005623 hasConceptScore W2989005623C89560881 @default.
• W2989005623 hasConceptScore W2989005623C90924648 @default.
• W2989005623 hasIssue "Supplement_1" @default.
• W2989005623 hasLocation W29890056231 @default.
• W2989005623 hasOpenAccess W2989005623 @default.
• W2989005623 hasPrimaryLocation W29890056231 @default.
• W2989005623 hasRelatedWork W2004684255 @default.
• W2989005623 hasRelatedWork W2005361433 @default.
• W2989005623 hasRelatedWork W2020778871 @default.
• W2989005623 hasRelatedWork W2067061757 @default.
• W2989005623 hasRelatedWork W2160322432 @default.
• W2989005623 hasRelatedWork W2563658598 @default.
• W2989005623 hasRelatedWork W2970265485 @default.
• W2989005623 hasRelatedWork W2989005623 @default.
• W2989005623 hasRelatedWork W3002276892 @default.
• W2989005623 hasRelatedWork W3021332379 @default.
• W2989005623 hasVolume "134" @default.
• W2989005623 isParatext "false" @default.
• W2989005623 isRetracted "false" @default.
• W2989005623 magId "2989005623" @default.
• W2989005623 workType "article" @default.